WO2022037470A3 - Long-acting insulin analog - Google Patents

Long-acting insulin analog Download PDF

Info

Publication number
WO2022037470A3
WO2022037470A3 PCT/CN2021/112215 CN2021112215W WO2022037470A3 WO 2022037470 A3 WO2022037470 A3 WO 2022037470A3 CN 2021112215 W CN2021112215 W CN 2021112215W WO 2022037470 A3 WO2022037470 A3 WO 2022037470A3
Authority
WO
WIPO (PCT)
Prior art keywords
long
acting insulin
insulin analog
diabetes
type
Prior art date
Application number
PCT/CN2021/112215
Other languages
French (fr)
Chinese (zh)
Other versions
WO2022037470A2 (en
Inventor
周述靓
王鹏
邓岚
Original Assignee
成都奥达生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 成都奥达生物科技有限公司 filed Critical 成都奥达生物科技有限公司
Publication of WO2022037470A2 publication Critical patent/WO2022037470A2/en
Publication of WO2022037470A3 publication Critical patent/WO2022037470A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is a long-acting insulin analog and a composition for preparing a drug for treating diseases, able to treat type I diabetes, type II diabetes, and gestational diabetes.
PCT/CN2021/112215 2020-08-17 2021-08-12 Long-acting insulin analog WO2022037470A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010826813.1 2020-08-17
CN202010826813.1A CN114075275A (en) 2020-08-17 2020-08-17 Long-acting insulin analogue

Publications (2)

Publication Number Publication Date
WO2022037470A2 WO2022037470A2 (en) 2022-02-24
WO2022037470A3 true WO2022037470A3 (en) 2022-04-07

Family

ID=80280823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/112215 WO2022037470A2 (en) 2020-08-17 2021-08-12 Long-acting insulin analog

Country Status (2)

Country Link
CN (1) CN114075275A (en)
WO (1) WO2022037470A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008330A (en) 2021-01-20 2024-01-18 Viking Therapeutics Inc Compositions and methods for the treatment of metabolic and liver disorders.
CN117586376A (en) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 Long-acting insulin compound

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043719A (en) * 1988-12-23 1990-07-11 诺沃-诺迪斯克有限公司 The preparation method of human insulin analogue
CN1163574A (en) * 1994-11-17 1997-10-29 伊莱利利公司 Acylated insulin analogs
CN101955527A (en) * 2003-08-05 2011-01-26 诺沃挪第克公司 Novel insulin derivates
CN104892749A (en) * 2015-06-16 2015-09-09 珠海联邦制药股份有限公司 Preparation method and application of insulin degludec crystal
CN107141350A (en) * 2017-06-23 2017-09-08 中国科学技术大学先进技术研究院 A kind of insulin analog and its synthetic method
CN110590934A (en) * 2019-09-25 2019-12-20 成都奥达生物科技有限公司 GLP-1 compound
CN111333714A (en) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 Long-acting GLP-1 compound
CN111410687A (en) * 2020-02-21 2020-07-14 成都奥达生物科技有限公司 Long-acting G L P-1 compound
CN111423506A (en) * 2019-11-08 2020-07-17 成都奥达生物科技有限公司 G L P-1 compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827284B (en) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 With the Exendin of polyethylene group or its analogue and preparation thereof and purposes
JP2013505221A (en) * 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス Long acting Y2 receptor agonist
JP6054861B2 (en) * 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス New glucagon analogues
AR100639A1 (en) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
CN110551203B (en) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 Exenatide analogue

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043719A (en) * 1988-12-23 1990-07-11 诺沃-诺迪斯克有限公司 The preparation method of human insulin analogue
CN1163574A (en) * 1994-11-17 1997-10-29 伊莱利利公司 Acylated insulin analogs
CN101955527A (en) * 2003-08-05 2011-01-26 诺沃挪第克公司 Novel insulin derivates
CN104892749A (en) * 2015-06-16 2015-09-09 珠海联邦制药股份有限公司 Preparation method and application of insulin degludec crystal
CN107141350A (en) * 2017-06-23 2017-09-08 中国科学技术大学先进技术研究院 A kind of insulin analog and its synthetic method
CN110590934A (en) * 2019-09-25 2019-12-20 成都奥达生物科技有限公司 GLP-1 compound
CN111423506A (en) * 2019-11-08 2020-07-17 成都奥达生物科技有限公司 G L P-1 compound
CN111410687A (en) * 2020-02-21 2020-07-14 成都奥达生物科技有限公司 Long-acting G L P-1 compound
CN111333714A (en) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 Long-acting GLP-1 compound

Also Published As

Publication number Publication date
CN114075275A (en) 2022-02-22
WO2022037470A2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
WO2022037470A3 (en) Long-acting insulin analog
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
MX2021013934A (en) Compounds and methods for the treatment of covid-19.
EA201692159A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING CONJUGATE BASED ON ANALOGUE INSULIN LONG-TERM ACTION AND CONJUGATE BASED ON ANALOGUE LONG-TERM POTTIDE PULSE OF LONG-TERM
EA201400030A1 (en) METHOD OF CONTINUOUS SUBDITIONAL INSULIN INJECTION WITH USE OF ENZYME DESTRUCTING HYALURONANE
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP3501546A3 (en) Cysteine drug conjugates and use of same
MX2011007854A (en) Methods for treating acute myocardial infarctions and associated disorders.
EP1594885B8 (en) Medicament for inhibiting tumour growth
MX2010009270A (en) Compounds and methods for the prevention or treatment of restenosis.
MX345032B (en) Selective ep4 receptor agonistic substance for treatment of cancer.
WO2023122783A3 (en) Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead
WO2023122784A3 (en) Spiros and related analogs for inhibiting yap/taz-tead
MX2021009170A (en) Crystal of diarylthiohydantoin compound.
MX362848B (en) Xanthine derivative.
MX2023013514A (en) Methods of treating interstitial cystitis/bladder pain syndrome.
MX2022012033A (en) Coronavirus infection treatment drug.
MX2023015068A (en) Glucagon analog and medical use thereof.
WO2024064807A3 (en) Methods of treating medulloblastoma with thyroid hormone
WO2008093764A1 (en) Composition for prevention or treatment of diabetes
MX2021011336A (en) Use of epidermal growth factor in diabetic foot ulcer treatment.
PH22019000675Y1 (en) A process of producing turmeric aqueous extract
PH22019000676U1 (en) Organic mulberry leaf water extract having anticlastogenic activity and method of production thereof
ZA202302772B (en) The process of preparation of vinegar by an aerobic condition
MX2014001855A (en) Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21857565

Country of ref document: EP

Kind code of ref document: A2